These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12525818)

  • 1. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.
    Claeys LG; Berg W
    Eur J Vasc Endovasc Surg; 2003 Jan; 25(1):85-7. PubMed ID: 12525818
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
    Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
    Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
    Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
    Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy.
    Jubelirer SJ; Koenig BA; Bates MC
    Am J Hematol; 1999 Jul; 61(3):205-8. PubMed ID: 10398314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA; Ganti AK; Levitt R; Potti A
    Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
    Berkowitz SD; Sane DC; Sigmon KN; Shavender JH; Harrington RA; Tcheng JE; Topol EJ; Califf RM
    J Am Coll Cardiol; 1998 Aug; 32(2):311-9. PubMed ID: 9708455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome.
    Vizzardi E; D'Aloia A; Zanini G; Antonioli E; Pedrinazzi C; Raddino R; Dei Cas L
    Intern Emerg Med; 2008 Dec; 3(4):345-7. PubMed ID: 18575821
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.
    Razakjr OA; Tan HC; Yip WL; Lim YT
    J Interv Cardiol; 2005 Feb; 18(1):33-7. PubMed ID: 15788052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute stent thrombosis associated with heparin-induced thrombocytopenia and abciximab-induced profound thrombocytopenia.
    Dasari TW; Pappy R; Hennebry TA
    J Invasive Cardiol; 2011 Feb; 23(2):E5-8. PubMed ID: 21297217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy.
    Jenkins LA; Lau S; Crawford M; Keung YK
    Circulation; 1998 Mar; 97(12):1214-5. PubMed ID: 9537353
    [No Abstract]   [Full Text] [Related]  

  • 14. Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents.
    Nowakowski K; Rogers J; Nelson G; Gunalingam B
    J Interv Cardiol; 2008 Feb; 21(1):100-5. PubMed ID: 18194210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.
    Golden T; Ghazala S; Wadeea R; Junna S
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia.
    Hayward CP
    Thromb Haemost; 2004 Oct; 92(4):674-5. PubMed ID: 15467893
    [No Abstract]   [Full Text] [Related]  

  • 17. Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab.
    Dobesh PP; Lakamp JE
    Am J Health Syst Pharm; 2002 Aug; 59(16):1539-42. PubMed ID: 12185830
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
    Butler R; Hubner PJ
    Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia.
    Holmes MB; Kabbani S; Watkins MW; Battle RW; Schneider DJ
    Circulation; 2000 Feb; 101(8):938-9. PubMed ID: 10694535
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F; Oza R; Mascarenhas DA
    J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.